An Open Label,Phase 3 Study of Telaprevir in Combination With Peginterferon Alfa 2a (Pegasys) and Ribavirin (Copegus) in Subjects Coinfected With Genotype 1 Hepatitis C Virus and Human Immunodeficiency Virus Type 1(HCV/HIV-1).
Phase of Trial: Phase III
Latest Information Update: 19 Mar 2015
At a glance
- Drugs Telaprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C; HIV-1 infections
- Focus Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 03 Mar 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 18 Apr 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 10 Jan 2014 Planned End Date changed from 1 Sep 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov